Advantages:
Industry leaders will join session participants to discuss the trade-offs caused by exploring new R&D models with the goal of creating value for your organizations.
Key Skills:
- How to approach business challenges with a different mindset.
- Effective alliance management and post-acquisition integration issues
- Appropriate assessment of the commercial value of your asset
- Recognition of key commercial value drivers
- Valuing appropriate and relevant commercial input in the value chain
- Appreciation of the pre-launch/launch and post-launch marketing activities
- Recognition of the critical commercial input to optimize your asset
MODULE A - CREATING VALUE
Networking Reception
Opening Night Welcome Reception | San Francisco, CA
Day 1
New Models of Innovation
Where does innovation come from and how do we get more of it? There are few more important questions to the biopharma industry and this year's BioExec Institute will feature some of the industries most respected thought leaders on the subject of innovation including Bernard Munos, Founder, InnoThink Center for Research in Biomedical Innovation and Mervyn J. Turner, Ph.D., Chief Strategy Officer, Merck & Co. Inc. & Sr. Vice President, Emerging Markets, Merck Research Laboratories.
- Where does innovation come from
- Emerging business opportunities in healthcare
- New models of early stage innovation
- The sustainability of the biopharma business model
Day 2
Disruptive Innovation - The External Insurrection
"High risk - high reward bets on innovation.”
A focus on innovative and/or niche models represented at specific companies which may or may not evolve into mainstream strategies. A high-level view of where current strategic investments are being made by ‘traditional’ biopharmas.
- Innovative therapies and models including delivery, price-point, and product service models
- Outcomes-based contracts for specialty medications
- Virtual company models
- Innovative R&D ecosystems
- Personalizing therapies
MODULE B - MANAGING VALUE
Day 3
Strategic Product Positioning
“Creation of commercial value for any asset starts at the research stage and parallels the entire R&D process.”
Companies often start development on new or improved products because of great technological innovations in the lab. But, ultimately, it is the market - the customer - who decides whether your product is valuable or not. Planning for commercial success starts at the research stage and parallels the entire R&D process. During this session, industry leaders will explore product commercialization, second generation products and potential exit strategies, all in an effort to determine the best way to optimize the value of innovation over time. The content in this session will range from high-level strategic trade-offs to detailed calculations of value (both quantitative and qualitative) and from debating options to understanding the path for optimizing your company's assets.
- Critical commercial decision points during the research and development phase of drugs
- Research and development decisions that have substantial commercial impact in the future
- Benefits and risks associated with commercial decisions during the development process
- Appropriate assessment of the commercial value of your asset
- Recognizing key commercial value drivers
- Value appropriate and relevant commercial input in the value chain
- Gain an appreciation for the pre-launch/launch and post-launch marketing activities
- Recognizing the critical commercial input to optimize your asset
Networking Reception
Mid-Point Networking Reception | Berkeley, CA 94704
Day 4
Successfully Operating in a Global Regulatory Environment
Bringing safe and effective pharmaceutical, medical device and diagnostics products to market requires careful navigation through significant regulatory challenges in a manner that is cost effective and timely. This session will provide an overview of the global regulatory framework as well as emerging trends and enforcement within the life sciences industry. Through real world experiences and case studies, you will gain an understanding of how companies can successfully operate within the global regulatory environment across the product value chain – Research & Development, Supply Chain and Manufacturing, and Commercial as well as explore some of the gray areas of moving the product through the complex and evolving regulatory process.
- Overview of FDA and international regulatory requirements including how these agencies work together to promote public health and safety
- Promoting Innovation, Product Safety, Quality, and Compliance in Product Development
- How does a company build quality into its upstream supply chain and manufacturing operations?
- Encouraging Good Promotional Practices and Compliance in Sales and Marketing
- Panel discussion regarding emerging regulatory trends and future challenges facing the life sciences industry
MODULE C - GROWING VALUE
Day 5
Deal-Maker for a Day
"How do different stakeholder's needs and roles shape the deal, the price and the commercialization pathway for a new therapy?”
Licensing and partnering are an integral part of the Biopharmaceutical industry. The formerly distinct pharmaceutical and biotechnology industries are merging into one interdependent Biopharmaceutical Industry. Partnered products are the future of innovation leading to a significant increase in attempts to acquire and/or license innovation from others. Big pharmaceutical companies will control fewer and fewer of their new products from discovery through line extension or OTC. This Day explores the underlying economics of deals; the different strategies for measuring risk; and how decisions are made amidst uncertainty.
- Financial trends in and pressures on the biopharma industry
- The deal market today and coming up
- The Buy-Side: What gets Big Pharma excited about an NME, regardless of who currently owns it?
- The Sell-Side: How to prepare an asset and a biotech company to get the best deal possible?
- De-risking the commercial prospects of a molecule
- How the molecule's commercial value impacts the deal
- Getting it in Writing: Making sure the contract reflects the business
- Success after the deal closes: Effective alliance management and post-acquisition integration issues
Networking Reception
Closing Networking Reception | Berkeley
"Making science into a company then scaling and selling ”
Being a successful CEO is a mix of timing, teams and some say luck. On Day 6 of the BioExec Institute you will not only have the opportunity to dialogue with some of the industries most respected CEOs who will provide detailed and candid accounts of what really happened, but you will become a CEO for the day. You will be asked to make strategic decisions based on little to no information; you will be faced with contentious Board Members and disgruntled employees. What will your financing or exit strategy be and who will you be crowned the Winner of CEO for a Day by BioExec Faculty?
